Neuroscience Trials Australia (NTA) is an Australian-based, niche, not-for-profit contract research organization (CRO) specializing in neuroscience clinical research. We provide a full-service solution across all Phase I-IV trials in Australia.
With a staff average of 14 plus years plus industry experience, we routinely work with pharmaceutical, biotechnology, cell therapy and device companies to undertake their clinical trials according to global regulatory standards, such that the data we collect is acceptable to regulatory authorities such as the TGA, FDA and EMA.
Due to NTA’s partnership with The Florey (the largest brain research institute in the southern hemisphere), NTA has strategic alliances with many therapeutic disease groups and we can provide access to key opinion leaders, experienced sites and clinical trial expertise through a range of tailored services. Across all our projects we interact with up to 200 CNS-focused sites alone. Any profit that NTA makes is re-directed back into neuroscience academic research at The Florey.
Our areas of expertise include (but are not limited to): epilepsy, stroke and stroke-related conditions, multiple sclerosis, Alzheimer’s disease/cognitive diseases, mental health, ALS/MND, Parkinson’s disease, spinal cord injuries, Huntington’s disease, neurosurgery, pain, neuromuscular disease and migraine, rare and pediatric disease, ophthalmology as well as first-in-human Phase I studies. NTA increasingly support our client’s portfolios in synergistic therapeutic indications including oncology tracers, immunology, ophthalmology, endocrinology, COVID-19, and sleep disorders. NTA’s experience extends to drugs (all classes including psychedelics), cell therapies, devices and diagnostics.